Mutant Calreticulin-Specific Monoclonal Antibody, INCA033989, is Well Tolerated and Achieves Rapid and Sustained Hematologic and Molecular Responses in Patients With Essential Thrombocythemia (SOHO 2026) - Sep 1, 2026 - Abstract #MPN-481; Location: LEVEL 3, HALL B3; P1 | "INCA033989 demonstrated favorable safety and efficacy in patients with mutCALR ET resistant/intolerant to cytoreductive treatment. Most patients achieved rapid, durable CHR correlating with decreased mutCALR VAF. DLT: dose-limiting toxicity, ET: essential thrombocythemia, MTD: maximum tolerated dose."
Clinical • Essential Thrombocythemia • Myelofibrosis • Myeloproliferative Neoplasm • Oncology • CALR
|
|
Haris Ali 1; Tania Jain 2; Aaron T Gerds 3; Vikas Gupta 4; Claire Harrison 5; Joan How 6; David Ross 7; Lucia Masarova 8; Bethan Psaila 9; Abdulraheem Yacoub 10; Terrence Bradley 11; Caroline McNamara 12; Andrew Perkins 13; William Shomali 14; Makoto Yoshimitsu 15; Junichiro Yuda 16; Haifa Kathrin Al-Ali 17; Lynette Chee 18; Jean-Jacques Kiladjian 19; Ruben Mesa 20; John Mascarenhas 29
|